



IBA RELEASES THE FIRST CYCLOTRON-BASED INTEGRATED COMMERCIAL PROTON THERAPY SYSTEM WITH PENCIL BEAM SCANNING

Embargo until 5:40 pm (Belgian time) – August 28, 2008

Louvain-la-Neuve, Belgium, August 28, 2008 – IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) announced today that its Pencil Beam Scanning (PBS) development is ready. This new feature is the result of an intensive and long development and confirms IBA's leadership in the field of proton therapy systems.

IBA is the first company with a cyclotron-based proton therapy system to submit a file to the FDA for Pencil Beam Scanning and expects market clearance upon completion of review by the FDA to be able to start marketing the system in the United States. Request for market clearance in other countries will be pursued in parallel, as needed.

"This feature has long been awaited by the proton therapy medical community", said Pierre Mottet, IBA's Chief Executive Officer. "IBA PBS technology will allow treating proton therapy cancer patients more precisely and more efficiently than ever before (better dose conformity to the treatment volume). Our capability to complete it first, well ahead of the competition, is a new demonstration of IBA's unmatched commitment to proton therapy and our efficacy to move the technology forward better and faster than anybody. While our competition invests in unsubstantiated marketing claims, we invest in making technology work for the benefit of patients. This first release of our Pencil Beam Scanning technology will pave the way towards even more advanced system capabilities in future versions of the technology currently under development. We are grateful to our partners at leading clinical institutions, particularly at MGH, FPTI and KNCC for their contribution in this development. It is because at IBA we work closely with our proton therapy customers that we understand the real challenges they face and their need for the most advanced treatment mode in proton therapy", continued Mr. Mottet.

Pencil Beam Scanning, once FDA approved, will be one of the four treatment modes included within the IBA Universal Nozzle. With the IBA Universal Nozzle, a proton therapy department has the flexibility to select the preferred beam delivery mode easily and automatically, without any manual intervention. Such flexibility in treatment modes represents an ideal solution for facilities that want to maximize their capabilities, with an increasing patient throughput. The IBA Universal Nozzle is designed to deliver the beam in four delivery modes: Single Scattering, Double Scattering, Uniform Scanning, and very soon Pencil Beam Scanning. Today, IBA is the only company offering such an all-in-one integrated system.

IBA is proving it is once again the world leader in proton therapy: with 13 proton therapy centers sold, of which 6 treating patients every day; capable of building multiple large facilities anywhere in the world and with the most advanced technologies.



Press Release |

ABOUT IBA

IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT and belongs to the BelMid index. Website: <http://www.iba-worldwide.com>

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations

Phone: +32 10 47 58 16

paul-emmanuel.goethals@iba-group.com